Cedars-Sinai investigators have discovered a healing mechanism that could one day be harnessed to help treat patients with spinal cord injuries, stroke, and neurological conditions such as multiple sclerosis. Their study, published in Nature, describes a previously unknown function of astrocytes, a type of cell in the central nervous system.
EPFL researchers have successfully engineered cells of the immune system to more effectively recognize cancer cells. The work, covered in two papers, turns the previously lab-based method into a full-blown immunotherapy strategy.
Stimulating the liver to produce some of the signals of the thymus can reverse age-related declines in T-cell populations and enhance response to vaccination.
CMR gained FDA marketing authorization for its first-generation Versius robot in October 2024 through the de novo pathway. In April, the company said it raised more than $200 million to support the commercialization of Versius.
A UK research team has developed a pioneering blood test that could change the way lung cancer is detected and monitored.
ALS is a debilitating paralytic disease characterized as the death of upper and lower motor neurons. Fortunately, ALS is relatively rare, with an incidence rate of 1.6 per 100,000 adults, resulting in about 30,000 cases in the United States at any one time.
A new artificial intelligence model could help design antibodies that better protect the body against viruses and disease. The AI model, known as ImmunoMatch, can predict and identify correct protein pairings within antibodies, potentially helping to strengthen the immune system. The research was conducted by a team from the University of Surrey and University College London and is published in Nature Methods.
BONADUZ, Switzerland, Dec. 16, 2025 /PRNewswire/ — Hamilton today announced the launch of GlucoSense, a breakthrough in bioprocess analytics that introduces the first reusable, in situ glucose sensor designed to deliver continuous, real-time measurements directly inside cell culture bioreactors.
Zephyrus Innovations (Zephyrus), a privately-owned medical device company designing and manufacturing safety syringes and Closed System Transfer Devices (CSTDs), today announces that it has received product 510(k) Marketing Clearance from the US Food and Drug Administration (“FDA”) for its VaporShield ™ CSTD.
New production capacity strengthens MPM Medical’s position as a leading U.S. manufacturer and follows the company’s recent launch of collagen at-home wound care kits